Illumina Reports Filing of New Patent Infringement Case Against Ariosa Diagnostics

Illumina (NASDAQ: ILMN) announced today that the company has filed a new patentinfringement suit against Ariosa Diagnostics, Inc. Illumina is seeking allavailable remedies, including injunctive relief.The new suit, filed in the U.S. District Court for the Northern District ofCalifornia, is based on Ariosa's infringement of U.S. Patent No. 7,955,794,entitled “Multiplex Nucleic Acid Reactions.” The suit targets Ariosa'sHarmony™ Prenatal Test, including its use of digital analysis of selectedregions (DANSR) that, among other things, enables simultaneous quantificationof hundreds of DNA loci.Verinata Health, now a wholly owned subsidiary of Illumina, previously suedAriosa for infringement of U.S. Patent No. 8,296,076 and U.S. Patent No.8,318,430 in the U.S. District Court for the Northern District of California.The Court in that case issued a Claim Construction Order providing the Court'sinterpretation of the disputed patent terms which supports the position thatAriosa infringes those patents.Illumina offers the verifi® non-invasive prenatal test (formerly offered byVerinata Health) in its CLIA-certified, CAP-accredited clinical serviceslaboratory, to detect chromosome abnormalities and aberrations with improvedresolution for consistent and dependable results. verifi® is the broadestnon-invasive prenatal test available today and is part of Illumina'scomprehensive reproductive and genetic health portfolio.